Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

• DOI: 10.1136/jitc-2020-000897
• Publication Date: 2020-10-22T21:23:00Z
• Authors: Ulrike Leiter; Carmen Loquai; Lydia Reinhardt; David Rafei-Shams...; Ralf Gutzmer; Katharina Kaehler; Lucie Heinzerling; Jessica C Hassel; Valerie Glutsch; Judith Sirokay; Nora Schlecht; Albert Rübben; Thilo Gambichler; Kerstin Schatton; Claudia Pfoehler; Cindy Franklin; Patrick Terheyden; Sebastian Haferkamp; Peter Mohr; Lena Bischof; Elisabeth Livings...; Lisa Zimmer; Michael Weichenthal; Dirk Schadendorf; Andreas Meiwes; Ulrike Keim; Claus Garbe; Jürgen Christian ...; Selma Ugurel
• Keywords: Concomitant; Hematologic malignancy; Hematological Malignancy; Immune checkpoint

Skin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI). However, considerable proportion patients with skin cancer is immuno-compromised by concomitant diseases. Due previous exclusion from clinical trials, the ICI poorly investigated in these patients. The present study analyzed outcome advanced hematological malignancy.This retrospective multicenter included who were treated locally or metastatic melanoma (MM), cutaneous squamous cell carcinoma (cSCC), Merkel (MCC), and had diagnosis malignancy irrespective disease activity need therapy at start. Comparator patient cohorts without extracted prospective registry ADOREG. Treatment was measured as best overall response, progression-free (PFS), survival (OS).84 (MM, n=52; cSCC, n=15; MCC, n=17) identified 20 centers. most frequent malignancies non-Hodgkin's lymphoma (n=70), chronic lymphocytic leukemia (n=32) being largest entity. While 9 received an adjuvant setting, 75 non-resectable (55 anti-PD-1; 8 anti-PD-L1; 5 anti-CTLA-4; 7 combinations). In latter patients, objective response (complete response+partial response) 28.0%, stabilization 25.3%, 38.6% showed progressive (PD). Subdivided entity, 31.1% 26.7% 18.8% (MCC). Median PFS 8.4 months 4.0 5.7 1-year OS rates 78.4% 65.8% 47.4% Comparison respective ADOREG (n=392) revealed no relevant differences MM but significantly reduced cSCC (p=0.002).ICI malignancy. Compared malignancy, observed impaired not MCC